Does semaglutide cause androgenic alopecia (pattern hair loss)?

Does Semaglutide Cause Androgenic Alopecia?

Semaglutide is associated with an increased risk of non-scarring alopecia, but this is primarily telogen effluvium (stress-related hair loss from rapid weight loss), NOT true androgenic alopecia (pattern baldness). The evidence shows a 40-76% increased risk of hair loss overall, but the mechanism and pattern differ fundamentally from androgen-driven pattern hair loss 1, 2, 3.

Understanding the Hair Loss Pattern

The critical distinction here is that androgenic alopecia is caused by androgen excess and DHT conversion in hair follicles 4, while semaglutide-associated hair loss appears to be:

• Telogen effluvium (76% increased risk) - diffuse shedding triggered by physiologic stress from rapid weight loss 1, 2
• Non-scarring alopecia (37-68% increased risk compared to other diabetes medications) 3
• NOT mediated by androgen pathways - the mechanism is weight loss-induced micronutrient deficiency and metabolic stress 1, 5

Key Evidence Points

From the most recent meta-analysis (2026): Pooled analysis of 1,091,743 patient-exposures showed semaglutide carries the highest pharmacovigilance burden (ROR 2.46) for hair loss, with telogen effluvium showing a 76% increased risk (aOR 1.76) but androgenetic alopecia showing only a 64% increase (aOR 1.64) - and this latter finding likely represents misclassification of telogen effluvium as pattern baldness 1.

From target trial emulation (2026): In 12,004 GLP-1 RA users, the hazard ratio for non-scarring alopecia was 1.37-1.68 compared to other diabetes medications, with the association specific to non-scarring subtypes 3.

From FDA labeling: The official prescribing information for semaglutide does NOT list alopecia or hair loss as a recognized adverse effect 6, though this may reflect the recency of these findings.

Clinical Implications

What This Means for Your Patient

1. If your patient develops hair loss on semaglutide:

   • Expect diffuse thinning across the scalp (telogen effluvium pattern)
   • NOT the vertex/crown-predominant pattern of true androgenic alopecia
   • Hair loss typically occurs 3-6 months after starting therapy or after significant weight loss
   • The association is strongest with semaglutide 2.4 mg weekly (weight loss dose) 1

2. Risk factors that increase likelihood:

   • Greater total weight loss (follow-up BMI was lower in those who developed hair loss) 2
   • Rapid weight loss velocity
   • Pre-existing nutritional deficiencies
   • Female sex (though data limited)

3. Paradoxical finding: In patients with central centrifugal cicatricial alopecia (a scarring form), 58% showed IMPROVEMENT with GLP-1 RA use, suggesting potential anti-inflammatory effects 1

Management Algorithm

When hair loss occurs on semaglutide:

1. Confirm the diagnosis:

   • Look for diffuse shedding without specific pattern
   • Pull test positive across entire scalp
   • Absence of miniaturization on dermoscopy (which would indicate true androgenic alopecia)

2. Assess for true androgen excess (if pattern suggests androgenic alopecia):

   • Measure total testosterone, free testosterone, DHEAS
   • Look for other signs: hirsutism, acne, menstrual irregularities
   • Remember: 15% of women with isolated alopecia have hyperandrogenemia 4

3. Optimize nutrition proactively:

   • Check and replete: iron, ferritin, vitamin D, zinc, B vitamins
   • Ensure adequate protein intake (1.2-1.5 g/kg during weight loss)
   • Consider prophylactic supplementation in high-risk patients

4. Do NOT discontinue semaglutide prematurely:

   • Telogen effluvium is self-limited (resolves 6-12 months after trigger)
   • The cardiovascular and metabolic benefits outweigh cosmetic concerns in most cases 7, 8, 9
   • Hair typically regrows once weight stabilizes

5. Consider adjunctive therapy:

   • Topical minoxidil 5% can accelerate recovery
   • Address any identified nutritional deficiencies
   • Reassure patient about expected timeline for recovery

Critical Caveats

• The absolute risk remains low - even with a 40-76% relative increase, most patients do NOT develop clinically significant hair loss 1, 3
• Causality is not definitively established - all current evidence is observational, with no prospective controlled trials 5
• Tirzepatide shows similar signals (ROR 1.73), suggesting this may be a class effect related to weight loss magnitude rather than GLP-1 mechanism specifically 1
• Alopecia areata (autoimmune) showed NO association (aOR 1.08, not significant), supporting the stress/nutritional mechanism over immune-mediated pathways 1

Bottom line: Counsel patients that hair thinning is possible (occurs in ~2-4% based on pharmacovigilance data) but is typically temporary, related to weight loss rather than hormonal changes, and should not prompt drug discontinuation given the substantial cardiometabolic benefits demonstrated in SELECT and other trials 8, 9.